Xeltis’ Post

Pulsed Field Ablation Innovator, Arga, has just raised €54 million in an oversubscribed financing round. The investors included Advent Life Sciences (UK), Earlybird Health (Germany), a new investor Gilde Healthcare (the Netherlands) as well as an undisclosed strategic investor. This start-up was founded by David Naele and Randy Werneth in 2020, to develop Coherent Sine-Burst Electroporation™ (CSE™), a next-generation cardiac ablation system for treating cardiac arrhythmias, including atrial fibrillation. Supporting Argá Medtech SA since its formation, Kellerhals Carrard advised on the Swiss contractual aspects of this round and collaborated with Wilson Sonsini Goodrich & Rosati from the US side. The Kellerhals Carrard team was led by Jean-Luc Chenaux (pictured) (Partner, M&A), and further comprised Frédéric Rochat (Partner, M&A), François Kaiser (Partner, M&A), Serge Migy (Partner, Tax) Virginie A. Rodieux (Partner, IP) as well as Cindy Liu-Ung and Joséphine Marmy (Senior Associates, M&A) and Brian Jurt (Tax advisor). Read the article >> https://lnkd.in/dJe2u5Qu #Legalcommunitych #legaladvisor #financinground

🔍 Andrei Gemeneanu, Managing Partner at Morphosis Capital, was invited as a speaker at the MIRSANU DEALMAKERS SUMMIT 2023, organized by the transaction journal MIRSANU.RO. During his presentations, Andrei Gemeneanu discussed the launch of the second fund of Morphosis Capital and the targeted investment strategy for it. 💬 "The Fund II will have a jump start at the end of this year, with an active pipeline planned for 2024. We aim to remain very consistent with the strategy from Fund I; the ticket size will increase slightly but not significantly. We are not changing our market segment. Our active focus is on the healthcare sector, where our success in forming three partnerships with prominent doctors in the Romanian medical community positions us favorably for ongoing investments in this area. Additionally, we are actively exploring opportunities in other sectors," stated Andrei Gemeneanu. #Morphosis #PrivateEquity #MIRSANU #event #Fund2

🔥 Join us for the 3rd H7 Angel Club meeting in 2024, happening on July 2nd at 3pm PST via Zoom！  🚩 Featured Company: A next-generation Non-degrading #MolecularGlue platform with significant competitive advantages. Founded by a pioneer who co-established the molecular glue field 33 years ago, the company recently secured a $28M #oversubscribed Series A+ round led by 3E Bioventures, Proxima Ventures, and Lapam Capital. 📣 H7 investment team has thoroughly reviewed the project and prepared a 📝[One-Pager Investment Teaser] along with a comprehensive ✍️ [Investment Report exceeding 30 pages]. Upon signing and NDA, we are delighted to provide access to the full report.  ----------- The meeting is exclusively for investor members of H7 Angel Club, which is entirely free for qualified investors. Apply for membership to attend. Upon approval, you’ll receive further details. 🎯Investor Membership Application: https://shorturl.at/losSW 🎯Founders Submitting Their Deck: https://shorturl.at/d3UBO #angel #investmentopportunity #vc #healthcare #lifesciences #medtech #medicaldevices #biotech #biopharma #investors #familyoffice #syndicate #fundraising #clinical

🔥 Join us for the 3rd H7 Angel Club meeting in 2024, happening on July 2nd at 3pm PST via Zoom！  🚩 Featured Company: A next-generation Non-degrading #MolecularGlue platform with significant competitive advantages. Founded by a pioneer who co-established the molecular glue field 33 years ago, the company recently secured a $28M #oversubscribed Series A+ round led by 3E Bioventures, Proxima Ventures, and Lapam Capital. 📣 H7 investment team has thoroughly reviewed the project and prepared a 📝[One-Pager Investment Teaser] along with a comprehensive ✍️ [Investment Report exceeding 30 pages]. Upon signing and NDA, we are delighted to provide access to the full report.  ----------- The meeting is exclusively for investor members of H7 Angel Club, which is entirely free for qualified investors. Apply for membership to attend. Upon approval, you’ll receive further details. 🎯Investor Membership Application: https://shorturl.at/losSW 🎯Founders Submitting Their Deck: https://shorturl.at/d3UBO #angel #investmentopportunity #vc #healthcare #lifesciences #medtech #medicaldevices #biotech #biopharma #investors #familyoffice #syndicate #fundraising #clinical

‘Next Wave of IPOs’ Will Arrive in Summer, Predicts Biotech-Focused VC Partner Delegates at the LSX World Conference in London seemed to agree on one thing—the biotech IPO window finally re-opened this year. This sentiment has persisted despite the fact that the initial run of public offerings died down by the spring. For Francesco De Rubertis, co-founder and partner of London-based life sciences investment firm Medicxi, the current lull is to be expected. What’s more, he expects “at least a number of IPOs” to arrive as soon as the summer. “In the absence of other external [factors], the natural dynamics of markets should say that now there will be another big number of investors that will become active on the public markets, and that will translate in the next wave of IPOs,” he told Fierce in an interview on the sidelines of the LSX conference. https://lnkd.in/d6ZB_eF3 #aspenalert #biotech #bioprocess

🔬 Kuano has closed a £1.8m seed funding round led by Mercia Ventures and including ACF Investors, Ascension Ventures, o2h Ventures, Meltwind Advisory LLP, and other angel investors. The investment will facilitate further validation of Kuano’s platform for the design of more effective potential drugs to target enzymes, as well as continued company growth through strategic partnerships and recruitment. Kuano is a drug discovery company combining quantum mechanics with AI to design the next generation of medicines. Read more ⏬ #VentureCapital #Investment #Funding #Growth #Medicine #QuantumMechanics #AI

🔬 Kuano has closed a £1.8m seed funding round led by Mercia Ventures and including ACF Investors, Ascension Ventures, o2h Ventures, Meltwind Advisory LLP, and other angel investors. The investment will facilitate further validation of Kuano’s platform for the design of more effective potential drugs to target enzymes, as well as continued company growth through strategic partnerships and recruitment. Kuano is a drug discovery company combining quantum mechanics with AI to design the next generation of medicines. Read more ⏬ #VentureCapital #Investment #Funding #Growth #Medicine #QuantumMechanics #AI

For this first trading updates of 2024, Eurazeo continues to grow its asset management activity and increases realizations. Eurazeo is focused on delivering its strategic and operational roadmap and confirms its positive outlook for 2024 with a rich and diversified fundraising pipeline. Since the beginning of the year, the Group has announced several exits across a wide range of its asset classes, all realized in good terms : Amolyt Pharma, Onfido, DORC Dutch Ophthalmic Research Center (International) and Peters Surgical. Eurazeo benefits from substantial leeway for its future investments.   📰 Read more: https://lnkd.in/e-8s5wUR   #PowerBetterGrowth #PrivateEquity #MidMarket #growth #impact #privatemarkets #economy #digitalisation #transition #ESG #fundraising

Commercialising research: the collaboration between tech transfer and investment. Listen to episode 10 of UCLB Big Talks on Big Impacts, as UCLB's CEO Dr Anne Lane chats to Dr Chris Hollowood, CEO of Syncona Limited . Anne and Chris discuss how Syncona came about, its close relationship with UCL and UCLB, the tech transfer ecosystem and what's next on the horizon for Syncona. In this episode, Chris shares his thoughts on the importance of a productive working relationship between founder and founding investor. He also reflects on Syncona's investment into UCLB spinout Autolus Therapeutics. "I think we went in with an initial premise around maybe one section that technology. But then as we got to know Martin, we saw the wider opportunity with everything in his lab. And that then became a £30 million Series A and a big company to build, but that was the initial attraction." UCL Innovation & Enterprise #UCLBBigTalks #Funding #TechTransfer Listen here: https://bit.ly/3QopxmZ

At these complex times, each success is amazing. Recently, it was inspiring to see not one, but several prominent achievements coming from the Israeli #healttech eco-system. Daria Lemann-Blumenthal, led BELKIN Vision to one of the most prominent strategic acquisitions in the Israeli #medtech. Keren Leshem, completed a successful $10mil fundraising for OCON Therapeutics , a remarkable milestone in the #womenhealth domain. These achievements are a testament to our resilience and proof that with the right approach, there is a way to create success against all odds! I invited Keren and Daria to join us for a MedTech Marketing at Scale #HealthTech #ExecutivePanel to speak about their recent journey and share insights, tips, and recommendations with our community. The panel will be joined by Dr. Avital Adler, PhD, Principal at aMoon Fund. Avital brings a broad perspective on the global private and public health-tech markets. She will speak about the market outline for #biotech , #digitalhealth, and #medicaldevices and discuss what turns the company into a success both in fundraising and IPO processes. I couldn't be more excited to put together and moderate such an inspiring panel. I invite you to join us and grab this unique chance to gain first-hand insights from these remarkable #womenleaders! Sign-up here: https://lnkd.in/d7_dnq4h #fundraising #strategic #acquisition #businesssuccess #knowledgesharing #partnership #marketingexpert #CMO